Clinical trials
Alcoholic Liver Disease clinical trials
Below are recruiting alcoholic liver disease clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07130318Recruiting
Mediterranean diet and exercise for fatty liver in FMF
This trial tests if a Mediterranean diet plus aerobic exercise can improve fatty liver in women with Familial Mediterranean Fever (FMF) who are also obese. It aims to see if these lifestyle changes help liver health.
Dokki, Giza GovernorateAges 30–55 - NCT06704321Recruiting
Effects of TOTUM-448 on liver fat and heart health
This trial tests a supplement called TOTUM-448 to see if it can reduce liver fat and improve heart health in people with a fatty liver condition (MASLD). If you have excess liver fat and are overweight, this study could help find new ways to manage your condition.
Québec, QuebecAges 18–75 - NCT00575133Recruiting
Study of people with fatty liver disease
This study follows people who have been confirmed to have fatty liver disease seen on a liver sample. It aims to understand the condition over time and how different causes and health factors may affect it.
Zurich, Canton of ZurichAges 18 years+ - NCT05255978Recruiting
Follow-up study for hepatitis B with fatty liver
This observational study looks at people with chronic hepatitis B who also have fatty liver (non-alcoholic fatty liver disease). It follows how their liver health changes over time and may help doctors understand outcomes and risk factors.
Wuhan, HubeiAges 18 years+ - NCT05546086Recruiting
Beijing health study for adults who live in Beijing
This study collects health information from adults (18+) who are permanent residents of Beijing. It aims to learn patterns about health in the local population and how different factors may affect outcomes over time.
BeijingAges 18 years+ - NCT05766449Recruiting
Study of liver inflammation and scarring in hepatitis B or fatty liver
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
NanjingAges 18 years+ - NCT05046483Recruiting
Blood sugar study after a new heart attack
This study measures how your body handles sugar and related hormones in people after a new STEMI heart attack, and compares them with people who do not have diabetes or have prediabetes. The goal is to better understand metabolic changes after the event, which could help future care.
Düsseldorf, North Rhine-WestphaliaAges 18–80 - NCT06061042Recruiting
Time-restricted eating for metabolic health
This study tests whether eating only during a specific time window each day can improve metabolic health in people with obesity and insulin resistance. If you have a high BMI and early signs of diabetes, this trial might help you understand a simple dietary change.
Amsterdam, North HollandAges 50–75 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT07726368RecruitingPhase 1
Study of ECC4703 with sulfasalazine and pitavastatin
This early-phase study tests how a new drug (ECC4703) works in the body when taken with two other common medications (sulfasalazine and pitavastatin). Healthy volunteers are needed to help researchers understand potential drug interactions and safety.
Melbourne, VictoriaAges 18–65 - NCT06649162Recruiting
Fatty liver risk in type 2 diabetes and new combo therapy
This study is looking at how often people with type 2 diabetes also have fatty liver disease, and whether a new combination medication (dapagliflozin and pioglitazone) can help manage both conditions.
Andong, Gyeongsangbuk-doAges 19 years+ - NCT06707129Recruiting
New criteria to see if NASH liver scarring has reversed
This study is creating better ways to measure if liver scarring from NASH (a type of fatty liver disease) has improved. It may help doctors know if treatments are working.
Beijing, Beijing MunicipalityAges 18–70 - NCT06694935RecruitingPhase 1
Testing QX1206 in type 2 diabetes with fatty liver
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
TorontoAges 18–64 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT06890169Recruiting
One-stop telehealth program for weight and diabetes
This trial tests a telehealth program that helps people lose weight and manage type 2 diabetes and fatty liver disease at the same time. It's a one-stop remote clinic that combines medical advice, nutrition, and lifestyle support.
SingaporeAges 21–70 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06895018Enrolling by invitation
Grape Drink Trial for Diabetes and Fatty Liver
This study tests a drink made from grape pomace (a natural byproduct) that is rich in polyphenols—compounds that may help the liver and heart. Participants have type 2 diabetes and mild fatty liver, and researchers want to see if the drink improves liver health, blood sugar, and gut bacteria over several months.
NaplesAges 35–70 - NCT06626074Recruiting
MRI study for NASH diagnosis
This study looks at MRI scans to find better ways to diagnose NASH (a type of fatty liver disease with inflammation). If you are already scheduled for a liver biopsy for suspected NASH, an MRI might help researchers learn more about your condition.
Angers, FranceAges 18 years+ - NCT06571474Recruiting
Fat Cell Function in Obesity and Metabolism Study
This study looks at how a type of immune cell (macrophage) in fat tissue processes lipids, and how that affects metabolism in people with different body weights. It may help us understand why some people with obesity develop diabetes and fatty liver while others do not.
Columbia, MissouriAges 18–70 - NCT06477146RecruitingPhase 2
Milk thistle for fatty liver in children and young adults
This trial tests whether milk thistle can help children and young adults with non-alcoholic fatty liver disease (NAFLD), a condition where fat builds up in the liver unrelated to alcohol use. It aims to see if the supplement can lower liver enzymes and improve liver health.
Cleveland, OhioAges 9–22 - NCT06354088RecruitingPhase 1
Study of alpelisib for insulin resistance
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
New York, New YorkAges 18–70
Hear when a new Alcoholic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcoholic liver disease?
- Yes. Clin2 currently lists 244 recruiting alcoholic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcoholic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcoholic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.